Editas Medicine Inc (EDIT)

04:03 AM

How to build a dashboard for Editas Medicine Inc. stock2025 Investor Takeaways & Community Consensus Trade Signals - newser.com

04:03 AM

12:21 PM

Can Editas Medicine Inc. stock sustain institutional interest2025 Stock Rankings & Free Real-Time Volume Trigger Notifications - newser.com

12:21 PM

11:28 AM

Why ETFs are accumulating Editas Medicine Inc. (8EM) stockQuarterly Earnings Report & Smart Allocation Stock Reports - Trung tâm Dự báo KTTV quốc gia

11:28 AM

12:45 PM

Can Editas Medicine Inc. stock weather global recessionPortfolio Value Summary & Risk Managed Investment Signals - newser.com

12:45 PM

Oct 16, 2025

Editas Medicine Inc. stock momentum explained2025 Sector Review & Proven Capital Preservation Methods - newser.com

Oct 16, 2025

Oct 16, 2025

Editas Medicine Inc. stock volume spike explainedWeekly Profit Summary & AI Optimized Trade Strategies - newser.com

Oct 16, 2025

Oct 16, 2025

Why Editas Medicine Inc. stock is in analyst buy zoneJuly 2025 Institutional & Risk Controlled Daily Plans - newser.com

Oct 16, 2025

Oct 15, 2025

Is Editas Medicine Inc. stock attractive after correction2025 Analyst Calls & Growth Focused Entry Reports - newser.com

Oct 15, 2025

Oct 15, 2025

How Editas Medicine Inc. (8EM) stock valuation compares with sectorPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com

Oct 15, 2025

Oct 14, 2025

Editas Medicine: Three Strikes And It's Out, Or Third Time’s The Charm? - Seeking Alpha

Oct 14, 2025

Oct 14, 2025

Editas Medicine at H. C. Wainwright: Aiming for LDL-C Breakthrough By Investing.com - Investing.com Canada

Oct 14, 2025

Oct 14, 2025

Using flow based indicators on Editas Medicine Inc.Trade Risk Summary & Technical Buy Zone Confirmations - newser.com

Oct 14, 2025

Oct 13, 2025

How high can Editas Medicine Inc. stock goWeekly Trend Report & Daily Profit Focused Stock Screening - newser.com

Oct 13, 2025

Oct 13, 2025

Published on: 2025-10-13 07:58:32 - newser.com

Oct 13, 2025

Oct 12, 2025

Published on: 2025-10-12 10:38:16 - newser.com

Oct 12, 2025

Oct 11, 2025

What analysts say about Editas Medicine Inc stockShort Interest Overview & Grow Smarter With Pro-Level Research - earlytimes.in

Oct 11, 2025

Oct 10, 2025

Editas Medicine Hits New 52-Week High of $4.05, Marking Key Milestone - Markets Mojo

Oct 10, 2025

Oct 10, 2025

Editas Medicine Inc 8EM Stock Analysis and ForecastSwing Trading Ideas & Free High Return Strategy Alerts - earlytimes.in

Oct 10, 2025

Oct 10, 2025

Leading vs lagging indicators on Editas Medicine Inc. performanceTrade Ideas & Technical Pattern Based Signals - newser.com

Oct 10, 2025

Oct 10, 2025

CRISPR Market Size, Share, Recent Developments, Growth - openPR.com

Oct 10, 2025

Oct 10, 2025

Regression analysis insights on Editas Medicine Inc. performanceQuarterly Earnings Report & High Conviction Buy Zone Alerts - newser.com

Oct 10, 2025

Oct 10, 2025

Is Editas Medicine Inc. (8EM) stock a top hedge fund pickBond Market & Low Drawdown Trading Strategies - newser.com

Oct 10, 2025

Oct 10, 2025

Editas Medicine (NASDAQ:EDIT) Receives Sell (E+) Rating from Weiss Ratings - MarketBeat

Oct 10, 2025

Oct 09, 2025

Editas Medicine Hits New 52-Week High at $4.07, Marking Significant Milestone - Markets Mojo

Oct 09, 2025

Oct 09, 2025

Editas Medicine Unveils Promising Preclinical Data on EDIT-401 - TipRanks

Oct 09, 2025

Oct 09, 2025

Editas Medicine Hits New 52-Week High of $4.54, Marking Significant Milestone - Markets Mojo

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL-C reduction in preclinical studies By Investing.com - Investing.com Nigeria

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL-C reduction in preclinical studies - Investing.com India

Oct 09, 2025

Oct 09, 2025

Editas Medicine (EDIT) Showcases Promising Preclinical Data for LDL Reduction - GuruFocus

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports Promising Preclinical Data for LDL-Cholesterol-Lowering Gene Editing Therapy EDIT-401 at ESGCT Congress - Quiver Quantitative

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - The Manila Times

Oct 09, 2025

Oct 09, 2025

Editas Medicine Reports In Vivo Proof-of-Concept Data for - GlobeNewswire

Oct 09, 2025

Oct 09, 2025

Editas Medicine reports 90% LDL cholesterol reduction in animal studies - StreetInsider

Oct 09, 2025

Oct 09, 2025

Editas Medicine Inc. stock retracement – recovery analysis2025 Trade Ideas & Weekly Top Performers Watchlists - newser.com

Oct 09, 2025

Oct 09, 2025

Best data tools to analyze Editas Medicine Inc. stockForecast Cut & Fast Entry High Yield Tips - newser.com

Oct 09, 2025